Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F
Division of Auxology, S. Giuseppe Hospital, Verbania, Italy.
Clin Endocrinol (Oxf). 1998 Jun;48(6):769-75. doi: 10.1046/j.1365-2265.1998.00435.x.
It is unclear whether the blunted GH secretion in Prader-Willi Syndrome (PWS) is a true deficiency, or merely secondary to obesity. We have investigated the role of obesity in the blunted GH secretion in PWS.
We studied the GH response to a combined administration of GHRH (1 microgram/kg i.v. at 0 min) and pyridostigmine (PD) (60 and 120 mg by mouth for children and adults, respectively, at time -60 min), as well as the baseline IGF-I levels, in a group of patients with PWS. Two different control groups were studied with GHRH + PD using the same doses and methods as above: prepubertal and pubertal obese subjects, and prepubertal short normal children. Moreover, in 14 patients with PWS and in the group of short normals the GH response to at least two stimulation tests (insulin tolerance test, clonidine, L-dopa, arginine) had been previously determined.
Twenty-two PWS patients (10 males and 12 females), 21 with essential obesity (11 males and 10 females), and eight short normal children (4 males and 4 females) were studied after obtaining informed consent.
Blood samples were taken at -60, -30 and 0 min and then 15, 30, 45, 60, 90 and 120 min after GHRH administration. Serum GH was measured in duplicate by IRMA, and IGF-I by RIA after acid ethanol extraction. Statistical analysis was performed by t-test for unpaired data, and analysis of variance for parametric or nonparametric data, where appropriate.
The GH response to GHRH + PD was significantly lower in PWS patients (AUC: mean +/- SE: 599 +/- 99 micrograms/l/h) if compared with either short normal children (3294 +/- 461 micrograms/l/h: P < 0.0001) or obese subjects (1445 +/- 210 micrograms/l/h: P < 0.005). Low IGF-I concentrations were found in all PWS patients, so that PWS group had mean IGF-I levels significantly lower than the other groups.
Our results showed that subjects with PWS had a reduced GH responsiveness to GHRH + PD associated with subnormal IGF-I levels. These findings suggested that short stature in PWS may be at least partially correlated to the presence of GH deficiency, and that impaired GH secretion is not secondary to obesity.
普拉德-威利综合征(PWS)患者生长激素(GH)分泌减弱是真正的缺乏,还是仅仅继发于肥胖,目前尚不清楚。我们研究了肥胖在PWS患者GH分泌减弱中所起的作用。
我们研究了一组PWS患者对联合给予生长激素释放激素(GHRH,0分钟时静脉注射1微克/千克)和吡啶斯的明(PD,儿童和成人分别在-60分钟时口服60毫克和120毫克)的GH反应,以及基线胰岛素样生长因子-I(IGF-I)水平。使用与上述相同的剂量和方法,对两个不同的对照组进行GHRH + PD研究:青春期前和青春期肥胖受试者,以及青春期前身材矮小的正常儿童。此外,之前已确定了14例PWS患者和身材矮小正常儿童组对至少两种刺激试验(胰岛素耐量试验、可乐定、左旋多巴、精氨酸)的GH反应。
在获得知情同意后,对22例PWS患者(10例男性和12例女性)、21例单纯性肥胖患者(11例男性和10例女性)和8例身材矮小正常儿童(4例男性和4例女性)进行了研究。
在-60、-30和0分钟时采集血样,然后在给予GHRH后15、30、45、60、90和120分钟采集血样。血清GH通过免疫放射分析(IRMA)进行双份测定,IGF-I在酸性乙醇提取后通过放射免疫分析(RIA)测定。对不成对数据采用t检验进行统计分析,对参数或非参数数据在适当情况下采用方差分析。
与身材矮小正常儿童(3294±461微克/升/小时:P < 0.0001)或肥胖受试者(1445±210微克/升/小时:P < 0.005)相比,PWS患者对GHRH + PD的GH反应显著降低(曲线下面积:平均值±标准误:599±99微克/升/小时)。所有PWS患者的IGF-I浓度均较低,因此PWS组的平均IGF-I水平显著低于其他组。
我们的结果表明,PWS患者对GHRH + PD的GH反应性降低,且IGF-I水平低于正常。这些发现提示,PWS患者身材矮小可能至少部分与GH缺乏有关,且GH分泌受损并非继发于肥胖。